HPV疫苗有望纳入国家免疫规划

Core Insights - The first domestically produced nine-valent HPV vaccine has opened for appointments and is being administered nationwide, with the vaccination range expanded to ages 9 to 17 [1] - Currently, there are six approved HPV vaccines in China, with three being imported and three domestically produced, previously dominated by imported products [1] - The inclusion of HPV vaccines in the national immunization program is expected to enhance accessibility and contribute to the goal of "eliminating cervical cancer" [1][2] Group 1 - The domestic HPV vaccine market is seeing increased competition, leading to a decrease in prices and improved accessibility for the population [1] - As of now, 149 countries have included HPV vaccines in their national immunization programs, with an average vaccination rate of about 60% [1] - Countries like Canada, Australia, and the UK have achieved high vaccination rates of 86%, 71%, and 68% respectively in 2023 [1] Group 2 - Australia's multi-tiered service system for HPV vaccination includes school-based programs and community clinics, which could serve as a model for China's implementation [2] - Experts predict that the rollout of free HPV vaccines in China will be phased, initially targeting key populations before expanding to a broader audience [2] - The focus on university students as a key demographic for HPV prevention is based on public health strategies, emphasizing the high return on investment for health measures during this stage [2] Group 3 - The concept of "gender-neutral vaccination" is gaining traction, with studies indicating that widespread vaccination can significantly reduce cervical cancer cases by 90% [3] - Vaccination of both males and females can establish strong herd immunity, reducing the transmission of HPV and protecting the entire population [3] - The latest guidelines advocate for the importance of HPV vaccination for both genders, highlighting the broader health benefits of such an approach [3]